Related references
Note: Only part of the references are listed.Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Olga Pozdnyakova et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
B cells responses and cytokine production are regulated by their immune microenvironment
Monica I. Vazquez et al.
CYTOKINE (2015)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
Francesco Passamonti et al.
BLOOD (2014)
Therapy for myeloproliferative neoplasms: when, which agent, and how?
Holly L. Geyer et al.
BLOOD (2014)
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
Xiaoli Wang et al.
BLOOD (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
Ann Mullally et al.
BLOOD (2013)
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
Alfonso Quintas-Cardama et al.
BLOOD (2013)
Efficacy and safety of pegylated-interferon-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
Jean-Christophe Ianotto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Advances in myelofibrosis: a clinical case approach
John O. Mascarenhas et al.
HAEMATOLOGICA (2013)
Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms
Brady L. Stein et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2013)
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha
Thomas Stauffer Larsen et al.
LEUKEMIA RESEARCH (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
Richard T. Silver et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report
Richard T. Silver et al.
BLOOD (2011)
Normal and malignant megakaryopoiesis
Qiang Wen et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis
R. T. Silver et al.
LEUKEMIA (2009)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1low mice
L Centurione et al.
BLOOD (2004)
Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487) -: A trial of the eastern cooperative oncology group
AI Radin et al.
CANCER (2003)
Share Paper
